Shares of VISEN PHARMA-B (02561) experienced a significant rise of more than 15% during the morning trading session. At the time of writing, the stock was up 15.22%, trading at HK$23.02 with a turnover of HK$1.482 million.

The notable increase follows the company's recent announcement of a project collaboration with Magical Health, a leading diversified healthcare payment platform in China. The partnership aims to leverage the respective strengths of both parties in the fields of innovative therapies and health services.

Focus of the Collaboration

Together, they will explore multiple pathways to enhance the accessibility and affordability of innovative treatments for endocrine diseases. The ultimate goal is to help patients in China more conveniently benefit from cutting-edge global therapeutic solutions.

Executive Commentary

Chen Jun, Chief Commercial Officer of VISEN PHARMA-B, commented on the strategic move. He stated that the company has consistently focused on introducing "first-in-class" or "best-in-class" innovative therapies to the Chinese market. The mission extends beyond making treatments available to ensuring patients have access to high-quality medicines.

He highlighted that VISEN possesses globally advanced endocrine innovation therapies, while Magical Health brings extensive practical experience in diversified payment solutions. This collaboration is expected to accelerate the process of making their innovative products accessible to a wider patient population, effectively bridging the gap from "having medicine available" to "being able to afford the medicine."